Press & News
People are different and so is their cancer, patients should be treated individually.
New The power of precision, For Every Oncologist, Today
With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality.
Outcome of the IndiTreat clinical trial (TICC) is published by ASCO prior to its Annual Meeting in June 2021.
2cureX Newsletter – ASCO update
ASCO Update – New Treatment strategy prolongs progression free survival in colorectal cancer patients
Redeye releases an updated 2cureX Equity Research Report
2curex update at Life Science Investor Conference, ØU Life Science Copenhagen 26/05’21
New Data 2cureX will be presented at ASCO 2021 (Biostock Article)
2cureX Newsletter May’21
2cureX unlocks the power of precision oncology (Biostock Article)
Interview with 2cureX CEO Fernando Andreu – Analyst Group
Get notified on mail, when news or press release is posted on our website